H.C. Wainwright Downgrades Celladon Corp (CLDN) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. PENG
4. NVDA
5. STZ
6. MSFT
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to H.C. Wainwright Downgrades Celladon Corp (CLDN) to Neutral

Celladon Reports Negative Results for CUPID2 Trial of MYDICAR(R) in Advanced Heart Failure

April 26, 2015 4:41 PM EDT

- Investigational gene therapy fails to meet primary and secondary endpoints - - Investor conference call and webcast Monday at 8:30 a.m. ET (5:30 a.m. PT) -

SAN DIEGO, April 26, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq: CLDN) today announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent MYDICAR® (AAV1/SERCA2a) versus placebo added to a maximal, optimized heart failure drug... More

Celladon Reports Negative Results for CUPID2 Trial of MYDICAR(R) in Advanced Heart Failure

April 26, 2015 4:41 PM EDT

- Investigational gene therapy fails to meet primary and secondary endpoints - - Investor conference call and webcast Monday at 8:30 a.m. ET (5:30 a.m. PT) -

SAN DIEGO, April 26, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq: CLDN) today announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent MYDICAR® (AAV1/SERCA2a) versus placebo added to a maximal, optimized heart failure drug... More